Genetech's psoriasis drug Raptiva might be defective as one side effect may be a progressive multifocal leukoencephalopathy (PML), a rare but serious, neurologic disease caused by a virus that affects the central nervous system.

This is an investigation and potential mass tort class action against Genentech in connection with its psoriasis therapy Raptiva.

Raptiva (efalizumab) was approved by the FDA in 2003. It is a once-weekly injection for adults with moderate to severe psoriasis. Psoriasis is a chronic immune system disorder that causes inflammation of the skin. This inflammation results in skin problems such as redness, itching or burning. Patients with psoriasis experience a situation in which their immune system sends faulty signals that increase the rate at which skin cells are grown.

Genentech has announced a voluntary, phased withdrawal of Raptiva from the U.S. market due to the potential risk to patients of developing progressive multifocal leukoencephalopathy (PML), a rare but serious, neurologic disease caused by a virus that affects the central nervous system.

Since the approval of Raptiva, the FDA has received reports of three confirmed cases and one possible case of progressive multifocal leukoencephalopathy (PML) in patients who were 47 to 73 years old using Raptiva for the treatment of psoriasis. Two of the patients with confirmed PML and one patient with possible PML died. All four patients were treated with Raptiva continuously for more than three years.


Symptoms and signs of neurological problems that could develop include the following:

Confusion
Dizziness
loss of balance
seizures
difficulty walking or talking

If you or someone you has experienced any adverse effects from their use of Raptiva, you should immediately consult your physician.

Do not change medications without first consulting your doctor.